Expedient synthesis of NOxy-Heterocyclic Carbenes (NOHC) ligands and metal complexes using mechanochemistry

Aneta Wróblewska, Gaëtan Lauriol, Grzegorz Mlostoń, Xavier Bantreil, Frédéric Lamaty

► To cite this version:

Aneta Wróblewska, Gaëtan Lauriol, Grzegorz Mlostoń, Xavier Bantreil, Frédéric Lamaty. Expedient synthesis of NOxy-Heterocyclic Carbenes (NOHC) ligands and metal complexes using mechanochemistry. *Journal of Organometallic Chemistry*, 2021, 949, pp.121914. 10.1016/j.jorganchem.2021.121914 . hal-03324425

HAL Id: hal-03324425

<https://hal.science/hal-03324425>

Submitted on 24 Aug 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Expedient synthesis of *N*-Oxy-Heterocyclic Carbenes (NOHC) ligands and metal complexes using mechanochemistry[☆]

Aneta Wróblewska^{a,*}, Gaëtan Lauriol^c, Grzegorz Mlostoń^b, Xavier Bantreil^c,
Frédéric Lamaty^{c,*}

^a Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Lodz, Poland

^b Department of Organic and Applied Chemistry, University of Lodz, Tamka 12, 91-403 Lodz, Poland

^c IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France

A B S T R A C T

1,3-Di(benzyloxy)imidazol-2-ylidenes (or NOHCs) possess structures related to *N*-heterocyclic carbenes (NHCs), with potentially useful applications including the stabilization of metals. In order to prepare NOHC metal complexes, a multi-step synthesis involving mechanochemistry, and making use of ball-milling, was designed. A library of unprecedented NOHC metal complexes were tested for their cytotoxic activities against HCT116 colorectal cancer cell line. The tests demonstrated that the studied complexes displayed a similar activity, comparable with that one exhibited by the ligand. However, a remarkable activity was found in the case of silver complex **5** with an IC₅₀ value of 0.75 μ M, comparable to that of doxorubicin.

1. Introduction

Mechanochemistry, defined as the use of mechanical forces to synthesize or degrade molecules, is currently recognized as an innovative technology that can facilitate the practical and sustainable preparation of both organic and inorganic compounds [1]. This approach, possibly involving mechanical milling, with the use of ball-mills, enables the development of solvent-free syntheses in a very efficient way [2,3]. Along with organic molecules, synthesized mechanochemically, ligands and discrete metal complexes have a place of choice since many advantages of this solid-state synthesis have found a direct illustration in this area [4-7]. It is worth citing (i) shorter reaction time (ii) elimination or significant decrease of the amount of reaction solvent (iii) facilitated purification resulting from more easily attained reaction completion. In most cases, metallic complexes are isolated by crystallization, and the combination of mechanosynthesis with this recovery technique makes it a very powerful methodology, useful in organic and organometallic chemistry as well.

N-heterocyclic carbenes (NHC) and their corresponding complexes have found an essential place in the area of coordination

chemistry. Since the discovery of 1,2-bis(adamantan-1-yl)imidazol-2-ylidene as a stable, crystalline compound, [8,9] the poor reputation about nucleophilic carbenes as laboratory curiosities changed dramatically and nowadays nucleophilic carbenes are recognized as useful substrates with diverse applications in catalysis (metallic and organic), [10-13] in material science [14] and biology [15,16]. In recent years, it has been shown that the mechanosynthesis of ligands and corresponding NHC complexes offers a very efficient approach to the target compounds (Scheme 1) [17-30]. Various types of NHC ligands could be prepared or employed, together with a wide range of metals such as Ag, Cu, Au, Pt, Ru, Pd, to prepare a new collection of organometallics. Of note, in general, the process is faster, cleaner, and, even, in some cases, providing products difficult or impossible to obtain via a solution synthesis. In recent years, numerous mechanosynthesized NHC complexes found attractive applications in catalysis [25,30,31] and medicinal chemistry [27].

4-Hydroxyl-imidazole 3-oxides and imidazolium salts derived therefrom constitute a group of heterocyclic compounds related to the NHCs since they can be considered as precursors of their oxy-analogues (NOHCs). Efficient methods for their preparation have been reported in recent decades, [32-35] but so far, the number of applications is rather limited. One can cite their usage as ionic liquids (in the form of corresponding imidazolium salt), [36-42] for biological applications, [43] as ligands for complexation of metals, [44-48] as additives in reactions [49,50] or as unique building

[☆] Dedicated to Prof. Elena Shubina on the occasion of her 70th birthday

* Corresponding author.

E-mail addresses: awroblew@cbmm.lodz.pl (A. Wróblewska), frederic.lamaty@umontpellier.fr (F. Lamaty).

Scheme 1. Mechanosynthesis of metalated NHCs and outline of the current work (vbm= vibratory ball mill).

blocks for the preparation of some co-crystals [51,52]. In our continuing studies on the preparation of this class of imidazole derivatives and owing to the success of the mechanochemical strategy for the preparation of NHCs, we decided to explore the mechanosynthesis of NOHCs and corresponding metal complexes, using a vibratory ball mill (vbm) (Scheme 1). In addition, another goal of the present study was the evaluation of the cytotoxicity of some of NOHCs and their complexes on the colorectal HCT116 cell line.

2. Results and discussion

2.1. Mechanosynthesis of NOHC ligands and metal-complexes

In a series of our recent papers, synthesis and reactivity of symmetric and non-symmetric di(alkyloxy)imidazol-2-ylidines have been described [43,53,54]. In solution, three efficient methods are reported for the preparation of 1,3-dialkoxy imidazolium salts **2** which are applied as precursors of NOHCs derived from imidazole [55]. The first synthetic approach is based on the initial preparation of 2-unsubstituted 1-alkoxy imidazole *N*-oxides, followed by *O*-alkylation by treatment with benzyl bromide or benzyl chloride as typical alkylating reagents [49]. The second method is based on a three component reaction between glyoxal, corresponding *N*-alkoxyamine, e.g. adamantyl-1-oxyamine, and formaldehyde in the presence of a strong Brønsted acid [56]. Finally, the third strategy comprises double *O*-alkylation of 1-hydroxyimidazole 3-oxides **1**, prepared initially from a diketone, hydroxylamine, and formaldehyde [55]. This latter method (Scheme 1) was selected for the development of the mechanosynthesis of 1,3-di(alkyloxy)imidazolium salts **2**, and subsequent preparation of corresponding 1,3-di(alkyloxy)imidazole-2-ylidenes metal complexes, including metals, such as Ag, Cu and Au.

The synthesis of starting 1-hydroxyimidazole *N*-oxides **1a-c** was carried out based on the method presented in Scheme 1. Inspired by the synthesis performed in solution, [49] corresponding diketone and hydroxylamine were mixed in a vibratory ball mill (vbm) for 1 h. Paraformaldehyde and a small amount of 36% HCl_{aq}, used together as the acid catalyst and additive for Liquid Assisted Grinding, [57–59] were added to the milling jar and mixed for another 1 h. Recovery of the reaction mixture and adjustment of the pH, as performed in classical solution synthesis, proved to be inefficient for isolation of the expected product. However, switching from 36% HCl_{aq} to acetic acid gave much better results. It has to be noted that the grinding could not be carried out in a stainless-steel jar because of its degradation resulting from the acidity of the reac-

tion medium. Instead, agate or zirconia-made jars and balls were preferred to develop an efficient procedure. Next, the crude reaction mixture was treated with aqueous ammonia and after separation of ammonium acetate, the products were purified by column chromatography. Compared to the synthesis in solution, the reaction was faster when performed in a ball mill (two times 1 h vs 20 h). Imidazole *N*-oxides **1a-c** were isolated as colorless solids and their structures were confirmed by spectroscopic analyses. In the case of **1a**, two ¹H NMR signals found at 7.09 ppm and 8.30 ppm were attributed to two equivalent H atoms, H(4) and H(5), and to H(2) atom, respectively (see Supporting Information). The ¹H NMR spectrum located at 2.10 (2 Me groups) the H(2) signal of **1c** was found as a singlet located at 8.01 ppm along with signals of aromatic C–H atoms found in the region 7.29–7.44 ppm.

Treatment of the starting *N*-oxides **1a-c** with a variety of methyl-substituted benzyl bromides in the presence of a base and MeOH as a liquid assistant to provide 1,3-di(benzyloxy)imidazolium salts **2** was also performed in a vibratory ball mill. The use of a base was necessary to remove the proton from the hydroxyl group located at N(1) of the imidazole ring. Among diverse bases (Cs₂CO₃, K₂CO₃, Na₂CO₃, NaHCO₃), which were tested during the optimization process of this reaction, the best results were achieved using Cs₂CO₃. In the case of **1a** and **1b**, benzylation led smoothly to the expected imidazole salts **2a-h** (Scheme 2). However, attempted benzylations of *N*-oxides **1c** was unsuccessful and, in all cases, led to a complex mixture of unidentified products. Very likely, the unsatisfactory course of this reaction resulted from the steric hindrance provided by the phenyl rings at C(4) and C(5) positions. Products **2a-h** were purified by filtration through a plug of celite. Here again, the mechanochemical approach offered an advantageous solvent-free procedure, with shorter reaction times (30 min) compared to experiments performed in solution (24–48 h).

The imidazolium salts **2** were soluble in organic solvents such as MeOH, CH₂Cl₂, CHCl₃, and the NMR spectra run in CDCl₃ solutions confirmed the symmetric structure of the studied molecules. For example, in the case of **2a**, a characteristic signal of C(2)H was down-field shifted compared to **1a** and appeared at 10.98 ppm and the signals of two equivalent CH₂ groups were found as a singlet at 5.53 ppm. In the ¹³C NMR spectra, one signal located at 117.8 ppm was attributed to two equivalent C(4) and C(5) atoms of the imidazole ring. The symmetric structure of all imidazolium salts **2b-h** was confirmed by analogous ¹H and ¹³C NMR data.

1	R ¹	Yield (%)	2, 3	R ¹	R ⁶	R ⁷	R ⁸	R ⁹	Yield of 2 (%)	Yield of 3 (%)
a	H	69	a	H	H	H	H	H	92	76
b	Me	89	b	H	H	Me	H	Me	98	91
c	Ph	56	c	H	H	H	Me	H	94	84
			d	H	Me	H	H	H	97	75
			e	Me	H	H	H	H	93	86
			f	Me	H	Me	H	Me	98	89
			g	Me	H	H	Me	H	97	85
			h	Me	Me	H	H	H	97	77

Scheme 2. Synthesis of 1,3-(dibenzyloxy)imidazolium bromides **2** and NOHC silver complexes **3**.

The next step of this study consisted in the preparation of NOHC metal complexes. Since silver complexes are recommended as entry materials to prepare other metalated products *via* transmetalation protocol, the mechanosynthesis of Ag complexes of the studied NOHCs **2** was next performed. It is known that NHC-silver complexes can easily be prepared in solution [60] or alternatively in a ball mill [18,19,21,27] by reaction of an imidazolium salt with Ag₂O. The previously optimized ball mill procedure was thus applied starting with a 1:0.5 mixture of a corresponding bis-alkylated imidazolium oxide salt **2** and Ag₂O, reacted neat in a milling jar agitated at 25 Hz.

In all cases, the experiment was finished after 30 min, and the desired complexes were isolated as pale yellow or colorless solids (Scheme 2). This procedure was applied successfully to precursors **2a-h** and actually, this is the first synthesis of monodentate 1,3-di(benzyloxy)imidazol-2-ylidene silver complexes. In the representative case of symmetric salt **2e**, the isolated complex **3e** was characterized spectroscopically, showing in the ¹H NMR spectrum two characteristic singlets located at 1.85 and 5.28 ppm corresponding to two equivalent Me and two equivalent benzylic CH₂ units, respectively. In the ¹³C NMR, the corresponding signals were found at 7.7 and 82.2 ppm, respectively. In addition, the absence of the C(2)H signal of the imidazole ring at ca. 11.72 ppm confirmed the elimination of the H-atom and the formation of the expected carbenic center. Apparently, the observed down-field shift of the signals attributed to the CH₂ groups results from the presence of oxygen atoms forming the N-O bond. The most characteristic C(2)-atom forming the carbenic center absorbed at 166.5 ppm. Similarly, the signals of the C(2) atoms in other complexes **3** were found in the region between 165.6–170.6 ppm. HRMS confirmed molecular formulas of complexes **3** with peaks corresponding to the [M-Br]⁺ ion.

Since, as reported earlier, NHC-homoleptic silver complexes were also synthesized mechanochemically, [19,27] starting with an imidazolium salt and Ag₂O, we also decided to apply this approach for the preparation of NOHCs silver analogues. The first step consisted in introducing a less coordinating anion by ball milling **2f** with KPF₆, and the anion metathesis provided the desired imidazolium **4** in 90% yield. Gratifyingly, grinding of imidazolium hexafluorophosphate salt **4** with 2 equivalents of Ag₂O furnished complex **5** in 87% yield after 4 h (Scheme 3).

The same product was also obtained in a one-jar stepwise procedure which involves anion exchange Br⁻ → PF₆⁻ as an initial step, achieved by 30 min of grinding bromide **2f** with an equimolar amount of KPF₆. Subsequent addition of Ag₂O and further grinding for 1 h led to a black powder. Filtration through a celite layer and evaporation of the solvent delivered the desired complex **5** in 80% yield (Scheme 3). It is worth mentioning that only a single example of such complexes, synthesized exclusively in solution, has yet been reported [47]. However, a longer reaction time (24 h) was required to complete the complexation reaction.

In analogy to complexes **3f**, signals of two equivalent Me groups appeared in ¹H NMR as a singlet found at 6.93 ppm along with four equivalent CH₂ benzyl groups located at 5.06 ppm. The molecular mass *M* = 835.3352 [M-PF₆]⁺ was confirmed by HRMS. Of note, all Ag-complexes **3** and **5** were light-sensitive substances that underwent a slow decomposition during the storage and for that reason, they had to be stored in the dark.

Anticipated structures of **2f** and **5** were unambiguously confirmed by single crystal X-ray diffraction analysis. The structure of **5** (Fig. 1a) was compared to the structure of cationic [Ag(**2f**)₂]PF₆ complex **6**, reported in the literature [47] (Fig. 1b).

Firstly, compared to imidazolium salt **2f**, the N-C-N angles in silver carbene **5** are smaller (104.4° in **2a** vs 99.8°/100.5° in **5**). This

Scheme 3. Synthesis of $[\text{Ag}(\text{NOHC})_2]\text{PF}_6$ -complex **5**.

Fig. 1. ORTEPs (at 50% probability level) of compounds (a) **5**, (b) **6** (from ref [47]). Hydrogen atoms are omitted for clarity.

observation is in agreement with reports and reviews from the literature [8,9,61]. Interestingly, silver complex **6** exhibits a linear arrangement of the two carbene ligands and the silver atom (angle C–Ag–C: 180°), while in complex **5** the C–Ag–C arrangement presents a distortion with an angle of 168° . Furthermore,

the two molecules of NOHCs in complex **6** lie essentially in the same plane (angle of 5.4°). In sharp contrast, a twist of 31.5° is observed between the NOHCs molecules in **5**. Finally, the torsion angles between the NOHCs and the four benzyl substituents (angle N–O–CH₂–aryl) are quite different in each molecule: 159.1° , 159.1° , 178.5° , 178.5° in **7**, confirming that the benzyl substituents are pointing away from the center of the complex. In **5**, among these angles (170.5° , 171.9° , 64.2° , 67.1°) two of them have similar values as the ones in **6** (benzyl pointing away) while two are much smaller with benzyl substituent pointing more towards the C–Ag–C bonds. Most probably, methyl groups present on the NOHC frameworks and on the benzyl substituents in **5** exert steric effects, inducing the various distortions observed in the structure compared to **6**.

The mechanosynthesis of silver complexes into corresponding gold or copper complexes was tested using complex **3f**. Transmetalation of **3f** into a gold(I) complex was also performed in a ball mill by grinding a mixture of **3f** and $\text{AuCl}\cdot\text{SMe}_2$ complex without any solvent (Scheme 4). The reaction was complete after 1 h and after typical work-up, the gold(I) complex **7** was obtained in 87% yield. The postulated structure was confirmed spectroscopically. Compared with its Ag precursor **3f**, the diagnostic C(2) signal of the carbenic center was high-field shifted and appeared at 157.9 ppm.

Analogously, Ag complex **3f** was converted into the copper complex **8** by grinding with CuCl. In this case, the transmetalation was completed after 1 h and the pure product was isolated in 92% yield after filtration through a pad of celite layer (Scheme 4).

2.2. Biological testing

NHC metal complexes, including mechanosynthesized compounds, [27] have been tested in recent years on cancer cell lines and promising results were reported in some cases [15,16,56,62]. Because of their close structural similarity to NHCs, we investigated the possibility of the newly synthesized NOHC-stabilized metal complexes to display biological activities, all the more that, cytotoxic activities of alkylated imidazole *N*-oxides were already reported [43]. This represents the first report of a cytotoxicity test performed on this family of potential metallodrugs.

The NOHC-metal complexes were tested against HCT116 colorectal cancer cell lines and the IC₅₀ (half growth inhibition concentration) for the compounds that displayed the best activities in preliminary testing (see Supporting Information) was determined.

Scheme 4. Synthesis of NOHC-Au(I) complex **7** and NOHC-Cu(I) complex **8**.

Doxorubicin was used as a positive control and displayed an IC_{50} value of $0.81 \mu\text{M}$. First, we focused on complexes derived from imidazolium **2f** since corresponding silver complexes **3f** and **5**, gold complex **6** and copper complex **7** were available for comparison of their activities. Imidazolium **2f** displayed an activity of $7.5 \mu\text{M}$. The corresponding silver complex **3f** did not show much better activity ($7.1 \mu\text{M}$). To our disappointment, switching from silver to gold **7** or copper **8** did not result in a remarkable increase in the cytotoxicity of the tested compounds (8.70 and $7.8 \mu\text{M}$, respectively). Subsequently, silver complexes **3b-e** and **3g** were tested and it turned out that **3c**, **3d** and **3g** displayed such a low activity in preliminary cytotoxicity tests that further investigation of these compounds was not pursued. Interestingly, absence of methyl groups on the benzyloxy and keeping their presence on the NOHC backbone (complex **3e**) resulted in decreased activity, compared to **3f**, with an IC_{50} value down to $8.65 \mu\text{M}$. On the other hand, removing the methyl groups on the backbone and keeping one methyl at ortho position of the benzyloxy unit (complex **3h**) or two Me groups at meta position (complex **3b**) led to a slight increase of activity (5.6 and $4.68 \mu\text{M}$, respectively). Finally, the cationic bis-NOHC silver complex **5** gave the best result with a cytotoxicity of $0.75 \mu\text{M}$, similar to doxorubicin ($0.81 \mu\text{M}$), and about ten times more potent than corresponding ligand **2f** or mono-NOHC-silver complex **3f**. The observed improvement of activity could be a consequence of an increased stability of **3f**, leading to a slow release of the silver ion [56].

3. Experimental section

3.1. Synthesis of imidazolium bromides **2**

Imidazole *N*-oxide **1** (1.00 eq), benzyl bromide or its methyl-substituted derivative (2.2 eq), cesium carbonate (0.5 eq) and MeOH (in the case of **2b**, **2c**, **2f**, **2g**: $0.5 \mu\text{L}/\text{mg}$) were placed in a 10 mL stainless steel grinding jar with one stainless steel ball (1 cm diameter). The jar was closed and subjected to grinding for 30 min in the vibratory ball mill operated at 25 Hz. After that time, CHCl_3 was added to the reaction mixture and the resulting solution was filtrated through a pad of celite. The solvent was evaporated and the precipitate was washed several times with Et_2O to afford pure imidazolium bromide.

3.2. Synthesis of NOHC-Ag(I)-complexes **3**

Imidazolium bromide **2** (1.00 eq) and silver oxide(I) (0.5 eq) were placed in a 10 mL stainless steel grinding jar with one stainless steel ball (1 cm diameter). The jar was closed and subjected to grinding for 30 min in the vibratory ball mill operating at 25 Hz. After that time, CHCl_3 was added to the reaction mixture and the

resulting suspension was filtrated through a pad of celite. The solvent was evaporated and the obtained solid was washed several times with Et_2O to afford pure NOHC-Ag(I)-complex.

3.3. Synthesis of imidazolium hexafluorophosphate **4**

Imidazolium bromide **2f** (69.7 mg, 0.156 mmol, 1.00 eq) and potassium hexafluorophosphate (30.3 mg, 0.165 mmol, 1.05 eq) were placed in a 10 mL stainless steel grinding jar with one stainless steel ball (1 cm diameter). The total mass of the reagents has been calculated so that the milling load equals 10.55 mg/mL . The jar was closed and subjected to grinding for 30 min in the vibratory ball mill operated at 25 Hz. After that time, CHCl_3 was added to the reaction mixture and the resulting solution was filtrated through a pad of celite. The solvent was evaporated and the precipitate was washed several times with Et_2O to afford pure 1,3-di[(3,5-dimethylbenzyl)oxy]-4,5-dimethyl-1*H*-imidazol-3-ium hexafluorophosphate **4** (71.8 mg, 0.141 mmol, 90%) as colourless crystals. Mp. = $147\text{--}148^\circ\text{C}$.

^1H NMR (500 MHz, CDCl_3) δ 8.84 (s, 1H), 6.99 (s, 2H), 6.96 (s, 4H), 5.17 (s, 4H), 2.26 (s, 12H), 2.14 (s, 6H) ppm. ^{13}C NMR (126 MHz, CDCl_3) δ 138.8, 132.0, 131.3, 128.3, 126.2, 123.8, 85.0, 21.2, 7.2 ppm. ^{31}P NMR (202 MHz, CDCl_3) δ -143.97 (sept, $J = 714.9 \text{ Hz}$) ppm. ^{19}F NMR (470 MHz, CDCl_3) δ -72.31 (d, $J = 714.2 \text{ Hz}$) ppm.

HRMS (ESI/TOF) m/z : calcd for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_2$: 365.2229 [M-PF_6^-] $^+$; found: 365.2225.

IR (cm^{-1}): 3138 m, 2959 m, 1743s, 1606 m, 1445 m, 1378 m, 1211 m, 1077 w, 896 m, 826 s, 724 m, 610 m, 557 s, 522 m.

Anal. Calcd for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_2\text{F}_6\text{P}$: C, 54.12; H, 5.73; N, 5.49. Found: C, 54.12; H, 5.65; N, 5.46.

3.4. Synthesis of $[\text{Ag}(\text{NOHC})_2]\text{PF}_6$ -complex **5**

Method A: 1,3-Di[(3,5-dimethylbenzyl)oxy]-4,5-dimethyl-1*H*-imidazol-3-ium hexafluorophosphate **4** (51.2 mg, 0.100 mmol, 1.00 eq) and silver oxide (48.8 mg, 0.211 mmol, 2.10 eq) were placed in a 10 mL stainless steel grinding jar with one stainless steel ball (10 mm diameter). The total mass of the reagents was calculated so that the milling load equals 10.55 mg/mL . The jar was closed and subjected to grinding for 4 h in the vibratory ball mill operated at 25 Hz. The black powder was recovered with dichloromethane and the suspension was filtrated through a pad of celite. The filtrate was concentrated under vacuum to afford 1,3-di[(3,5-dimethylbenzyl)oxy]-4,5-dimethylimidazolyl-2-ene[silver hexafluorophosphate **5** (42.8 mg, 0.043 mmol, 87%) as a white solid.

Method B: 1,3-Di[(3,5-dimethylbenzyl)oxy]-4,5-dimethyl-1*H*-imidazol-3-ium bromide **2f** (39.9 mg, 0.090 mmol, 1.00 eq) and

Fig. 2. IC₅₀ (μM) values against HCT116 carcinoma cells.

potassium hexafluorophosphate (16.5 mg, 0.090 mmol, 1.00 eq) were placed in a 10 mL stainless steel grinding jar with one stainless steel ball (10 mm diameter). The jar was closed and subjected to grinding for 30 min in the vibratory ball mill operated at 25 Hz. Afterwards, silver oxide (43.6 mg, 0.188 mmol, 2.10 eq) was added. The total mass of the reagents was calculated so that the milling load equals 19.2 mg/mL. The jar was closed and subjected to grinding for 1 hour. The black powder was recovered with dichloromethane and filtrated through a pad of celite. The filtrate was concentrated under vacuum to afford 1,3-di[(3,5-dimethylbenzyl)oxy]-4,5-dimethylimidazol-2-ene]silver hexafluorophosphate **5** (35.1 mg, 0.0358 mmol, 80%) as a white solid. Mp. = 197–198 °C.

¹H NMR (500 MHz, CDCl₃) δ 6.93 (s, 12H), 5.06 (s, 8H), 2.20, 2.15 (2xs, 36H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 138.7, 132.6, 131.5, 128.0, 121.7, 82.9, 21.2, 7.8 ppm. ³¹P NMR (202 MHz, CDCl₃) δ -144.08 (sept, J = 707.9 Hz) ppm. ¹⁹F NMR (470 MHz, CDCl₃) δ -73.70 (d, J = 718.7 Hz) ppm.

HRMS (ESI/TOF) *m/z*: calcd for C₄₆H₅₆N₄O₄Ag: 835.3352 [M-PF₆]⁺; found: 835.3366.

IR (cm⁻¹): 3013 m, 2966 m, 1737s, 1605 w, 1442 m, 1366s, 1229 m, 1214 w, 1200 m, 1074 w, 945 m, 835 s, 715 m, 680 m, 554 m, 522 m.

Anal. Calcd for C₄₆H₅₆AgN₄O₄F₆P: C, 56.27; H, 5.75; N, 5.71. Found: C, 56.25; H, 5.83; N, 5.95.

3.5. Synthesis of NOHC-Au(I)-complex **7**

Imidazolium silver bromide **3f** (61.0 mg, 0.110 mmol, 1.00 eq) and chloro(dimethylsulfide)gold(I) (39.0 mg, 0.133 mmol, 1.20 eq) were placed in a 10 mL stainless steel grinding jar with one stainless steel ball (1 cm diameter). The total mass of the reagents has been calculated so that the milling load equals 10.55 mg/mL. The jar was closed and subjected to grinding for 1 h in the vibratory ball mill operated at 25 Hz. After that time, CHCl₃ was added to the reaction mixture and the resulting solution was filtrated through a pad of celite. The solvent was evaporated, and the precipitate was washed several times with Et₂O to afford pure 1,3-di[(3,5-dimethylbenzyl)oxy]-4,5-dimethylimidazol-2-ylidene]gold chloride **7** (57.2 mg, 0.096 mmol, 87%) as colourless crystals. Mp. = 217–218 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.08–7.01 (m, 6H), 5.29 (s, 4H), 2.32 (s, 12H), 1.92 (s, 6H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 157.9, 138.6, 132.5, 131.6, 128.2, 120.8, 82.7, 21.3, 7.8 ppm.

HRMS (ESI/TOF): *m/z* calcd for C₂₃H₂₈N₂O₂Au₁Cl₁Na₁: 619.1406 [M+Na⁺]; found: 619.1403, *m/z* calcd for C₂₃H₂₈N₂O₂Au₁: 561.1816 [M-Cl]⁺; found: 561.1818, *m/z* calcd for C₄₆H₅₆N₄O₄Au₁: 925.3967 [2M-AuCl₂]⁺; found: 952.3972.

IR (cm⁻¹): 2919 m, 1769 m, 1608 m, 1468 m, 1386 m, 1240 m, 1167 m, 1077 m, 943 s, 919 m, 849 s, 709 m, 674 s.

Anal. Calcd for C₂₃H₂₈AuClN₂O₂•0.2CH₂Cl₂: C, 45.39; H, 4.66; N, 4.56. Found: C, 45.17; H, 4.94; N, 4.61.

3.6. Synthesis of NOHC-Cu(I)-complex **8**

Imidazolium silver bromide **3f** (55.2 mg, 0.100 mmol, 1.00 eq) and copper(I) chloride (14.8 mg, 0.150 mmol, 1.50 eq) were placed in a 10 mL stainless steel grinding jar equipped with one stainless steel ball (1 cm diameter). The total mass of the reagents has been calculated so that the milling load equals 7.39 mg/mL. The jar was closed and subjected to grinding for 1 h in the vibratory ball mill operated at 25 Hz. After that time, CHCl₃ was added to the reaction mixture and the resulting solution was filtrated through a pad of celite. The solvent was evaporated, and the obtained solid was washed several times with Et₂O to afford pure 1,3-di[(3,5-dimethylbenzyl)oxy]-4,5-dimethylimidazol-2-ylidene]copper chloride **8** (42.6 mg, 0.092 mmol, 92%) as a pale yellow powder. Mp. = 175–176 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.02 (s, 6H), 5.18 (s, 4H), 2.32 (s, 12H), 1.92 (s, 6H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 138.7, 132.6, 131.5, 128.1, 120.7, 82.9, 21.3, 7.6 ppm.

HRMS (ESI/TOF): *m/z* calcd for C₂₃H₂₈N₂O₂Cu₁Cl₁Na₁: 485.1033 [M+Na⁺]; found: 485.1035, *m/z* calcd for C₂₃H₂₈N₂O₂Cu₁: 427.1447 [M-Cl]⁺; found: 427.1447, *m/z* calcd for C₄₆H₅₆N₄O₄Cu₁: 791.3598 [2M-CuCl₂]⁺; found: 791.3605.

IR (cm⁻¹): 2916 m, 1757 m, 1643 m, 1608 m, 1456 m, 1380 m, 1167 m, 1077 m, 1036 m, 942 m, 893 m, 849 s, 683 s, 665 m.

Anal. Calcd for C₂₃H₂₈ClCuN₂O₂•0.2CH₂Cl₂: C, 58.26; H, 5.98; N, 5.87. Found: C, 58.26; H, 5.99; N, 6.00.

4. Conclusions

A multi-step mechanosynthesis of 1,3-di(benzyl)oxyimidazol-2-ylidene metal complexes is described. Starting *N*-hydroxy imida-

zole *N*-oxides were prepared from respective substrates by reaction in a vibratory ball-mill. This initial step was followed by *O*-benzylation, and subsequent metalation which were also performed in a vbm. In these three steps, mechanical milling provided an essentially solvent-free procedure with considerable reduction of the reaction times. These protocols opened the route to an efficient preparation of new 1,3-di(benzyloxy)imidazol-2-ylidene silver, and gold and copper complexes. Two latter representatives were obtained *via* mechanotransmetalation approach. All new complexes were characterized spectroscopically and two of them were subjected to single crystal X-ray analysis. In extension of the study, new NOHCs complexes were evaluated for their cytotoxic activity against the HCT116 colorectal cancer cell line. Homoleptic silver complex **5** displayed remarkably high activity, similar to the known doxorubicin. These reported results demonstrate once more that mechanochemistry can be exploited as a well-adapted method for the preparation of NOHCs and corresponding metallic complexes. Furthermore, this work supports the validity of a strategical approach to discover new metallodrugs based on the principles of medicinal mechanochemistry [27,63–65].

Fig. 2

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors thank for financial support the National Science Center (Cracow, Poland) within the Projects: OPUS-13 Grant no. 2017/25/B/ST4/02684 (A.W.) and BEETHOVEN-2 Grant no. 2016/23/G/ST5/04115 (G.M.), the University of Montpellier and the CNRS. G.M. thanks Professor Peter R. Schreiner (Giessen) for valuable discussion on the chemistry of nucleophilic heterocyclic carbenes (NOHC type).

References

- [1] F. Gomollón-Bel, *Chem. Int.* 41 (2019) 12.
- [2] J.L. Howard, Q. Cao, D.L. Browne, *Chem. Sci.* 9 (2018) 3080.
- [3] T. Friščić, C. Mottillo, H.M. Titi, *Angew. Chem., Int. Ed.* 59 (2020) 1018.
- [4] A.L. Garay, A. Pichon, S.L. James, *Chem. Soc. Rev.* 36 (2007) 846.
- [5] N.R. Rightmire, T.P. Hanusa, *Dalton Trans.* 45 (2016) 2352.
- [6] A.A. Geciauskaite, F. García, Beilstein J. Org. Chem. 13 (2017) 2068.
- [7] A. Beillard, X. Bantreil, T.-X. Métro, J. Martinez, F. Lamaty, *Chem. Rev.* 119 (2019) 7529.
- [8] A.J. Arduengo, R.L. III; Harlow, M. Kline, *J. Am. Chem. Soc.* 113 (1991) 361.
- [9] A.J. Arduengo III, H.V.R. Dias, R.L. Harlow, M. Kline, *J. Am. Chem. Soc.* 114 (1992) 5530.
- [10] S. Diez-Gonzalez, N. Marion, S.P. Nolan, *Chem. Rev.* 109 (2009) 3612.
- [11] E. Colacino, J. Martinez, F. Lamaty, *Coord. Chem. Rev.* 251 (2007) 726.
- [12] L.-A. Schaper, S.J. Hock, W.A. Herrmann, F.E. Kuehn, *Angew. Chem., Int. Ed.* 52 (2013) 270.
- [13] D.M. Flanigan, F. Romanov-Michailidis, N.A. White, T. Rovis, *Chem. Rev.* 115 (2015) 9307.
- [14] R. Visbal, M.C. Gimeno, *Chem. Soc. Rev.* 43 (2014) 3551.
- [15] S.Y. Hussaini, R.A. Haque, M.R. Razali, *J. Organomet. Chem.* 882 (2019) 96.
- [16] M. Mora, M.C. Gimeno, R. Visbal, *Chem. Soc. Rev.* 48 (2019) 447.
- [17] C.J. Adams, M. Lusi, E.M. Mutambi, A. Guy Orpen, *Chem. Commun.* 51 (2015) 9632.
- [18] A. Beillard, E. Golliard, V. Gillet, X. Bantreil, T.-X. Métro, J. Martinez, F. Lamaty, *Chem. Eur. J.* 21 (2015) 17614.
- [19] A. Beillard, X. Bantreil, T.-X. Métro, J. Martinez, F. Lamaty, *Dalton Trans.* 45 (2016) 17859.
- [20] C.J. Adams, M. Lusi, E.M. Mutambi, A.G. Orpen, *Cryst. Growth Des.* 17 (2017) 3151.
- [21] A. Beillard, X. Bantreil, T.-X. Métro, J. Martinez, F. Lamaty, *New J. Chem.* 41 (2017) 1057.
- [22] A. Beillard, T.-X. Métro, X. Bantreil, J. Martinez, F. Lamaty, *Chem. Sci.* 8 (2017) 1086.
- [23] A. Beillard, X. Bantreil, T.-X. Métro, J. Martinez, F. Lamaty, *Green Chem.* 20 (2018) 964.
- [24] I.E. Chikunov, G.S. Ranny, A.V. Astakhov, V.A. Tafeenko, V.M. Chernyshev, *Russ. Chem. Bull.* 67 (2018) 2003.
- [25] N. Mukherjee, A. Marczyk, G. Szczepaniak, A. Sytniczuk, A. Kajetanowicz, K. Grellard, *ChemCatChem* 11 (2019) 5362.
- [26] R.J. Allenbaugh, J.R. Zachary, A.N. Underwood, J.D. Bryson, J.R. Williams, A. Shaw, *Inorg. Chem. Commun.* 111 (2020) 107622.
- [27] A. Beillard, F. Quintin, J. Gatignol, P. Retailleau, J.-L. Renaud, S. Gaillard, T.-X. Métro, F. Lamaty, X. Bantreil, *Dalton Trans.* 49 (2020) 12592.
- [28] S. De, F. Joo, H. Horvath, A. Udvardy, C.E. Czegeni, *J. Organomet. Chem.* 918 (2020) 121308.
- [29] G. Pisano, C.S.J. Cazin, *Green Chem.* 22 (2020) 5253.
- [30] F. Quintin, J. Pinaud, F. Lamaty, X. Bantreil, *Organometallics* 39 (2020) 636.
- [31] A. Beillard, T.-X. Métro, X. Bantreil, J. Martinez, F. Lamaty, *Eur. J. Org. Chem.* 2017 (2017) 4642.
- [32] La Parola, G. Gazz, *Chim. Ital.* 75 (1945) 216.
- [33] J.B. Wright, *J. Org. Chem.* 29 (1964) 1620.
- [34] K. Bodendorf, H. Towliati, *Arch. Pharm. (Weinheim)* 298 (1965) 293.
- [35] P. Franchetti, M. Grifantini, C. Lucarelli, M.L. Stein, *Farmaco, Ed. Sci.* 27 (1972) 46.
- [36] C. Froschauer, H.K. Weber, T. Roeder, H. Sixta, G. Laus, B. Lendl, H. Schottenberger, *Lenzinger Ber* 91 (2013) 30.
- [37] M. Jochriem, C.G. Kirchler, G. Laus, K. Wurst, H. Kopacka, T. Mueller, H. Schottenberger, *Z. Naturforsch., B: J. Chem. Sci.* 72 (2017) 617.
- [38] F. Meischl, M. Harder, C.G. Kirchler, J. Kremser, C.W. Huck, G.K. Bonn, M. Rainer, *J. Mol. Liq.* 289 (2019) 111157.
- [39] M. Zeeshan, V. Nozari, S. Keskin, A. Uzun, *Ind. Eng. Chem. Res.* 58 (2019) 14124.
- [40] S. Huber, M. Harder, F. Funck, K. Erharter, M. Popp, G.K. Bonn, M. Rainer, *Separations* 7 (2020) 45.
- [41] M. Kreidl, M. Harder, M. Rainer, G.K. Bonn, *Anal. Methods* 12 (2020) 4377.
- [42] D. Bhawna; Dhingra, A. Pandey, S. Pandey, *J. Photochem. Photobiol., A* 406 (2021) 112991.
- [43] G. Młostoń, M. Celeda, W. Poper, M. Kowalczyk, K. Gach-Janczak, A. Janecka, M. Jasiński, *Materials (Basel)* 13 (2020) 4190.
- [44] G. Laus, A. Schwaerzler, P. Schuster, G. Bentivoglio, M. Hummel, K. Wurst, V. Kahlenberg, T. Loerting, J. Schuetz, P. Peringer, G. Bonn, G. Nauer, H. Schottenberger, *Z. Naturforsch., B: Chem. Sci.* 62 (2007) 295.
- [45] A.K. Guha, S. Sarmah, A.K. Phukan, *Dalton Trans.* 39 (2010) 7374.
- [46] M. Freindorf, D. Cremer, E. Kraka, *Mol. Phys.* 116 (2018) 611.
- [47] G. Laus, K. Wurst, V. Kahlenberg, H. Kopacka, C. Kreutz, H. Schottenberger, *Z. Naturforsch., B: J. Chem. Sci.* 65 (2010) 776.
- [48] B. Rietzler, G. Laus, V. Kahlenberg, H. Schottenberger, *Acta Crystallogr., Sect. E: Crystallogr. Commun.* 71 (2015) m251.
- [49] S. Bartz, B. Blumenroeder, A. Kern, J. Fleckenstein, S. Frohnappfel, J. Schatz, A. Wagner, *Z. Naturforsch., B: J. Chem. Sci.* 64 (2009) 629.
- [50] T. Brendgen, T. Fahlbusch, M. Frank, D.T. Schuehle, M. Sessler, J. Schatz, *Adv. Synth. Catal.* 351 (2009) 303.
- [51] M.K. Dudek, J. Śniechowska, A. Wróblewska, S. Kaźmierski, M.J. Potrzebowski, *Chem. - Eur. J.* 26 (2020) 13264.
- [52] A. Wróblewska, J. Śniechowska, S. Kaźmierski, E. Wielgus, G.D. Bujacz, G. Młostoń, A. Chworos, J. Suwara, M.J. Potrzebowski, *Pharmaceutics* 12 (2020) 359.
- [53] G. Młostoń, M. Celeda, K. Urbaniak, M. Jasiński, V. Bakhonsky, P.R. Schreiner, H. Heimgartner, Beilstein J. Org. Chem. 15 (2019) 497.
- [54] G. Młostoń, M. Celeda, M. Jasiński, K. Urbaniak, P.J. Boratyński, P.R. Schreiner, H. Heimgartner, *Molecules* 24 (2019) 4398.
- [55] G. Młostoń, M. Jasiński, A. Wróblewska, H. Heimgartner, *Curr. Org. Chem.* 20 (2016) 1359.
- [56] N.A. Johnson, M.R. Southerland, W.J. Youngs, *Molecules* 22 (2017) 1263/1.
- [57] G.A. Bowmaker, *Chem. Commun.* 49 (2013) 334.
- [58] V. Porte, M. Thioloy, T. Pigoux, T.-X. Métro, J. Martinez, F. Lamaty, *Eur. J. Org. Chem.* (2016) 3505.
- [59] D. Tan, F. García, *Chem. Soc. Rev.* 48 (2019) 2274.
- [60] H.M.J. Wang, I.J.B. Lin, *Organometallics* 17 (1998) 972.
- [61] F.E. Hahn, M.C. Jahnke, *Angew. Chem., Int. Ed.* 47 (2008) 3122.
- [62] Ott, I. In *Advances in Inorganic Chemistry*; Sadler, P. J., van Eldik, R., Eds.; Academic Press: 2020; Vol. 75, p 121.
- [63] D. Tan, L. Loots, T. Friščić, *Chem. Commun.* 52 (2016) 7760.
- [64] A.S. McCalmont, A. Ruiz, M.C. Lagunas, W.T. Al-Jamal, D.E. Crawford, *ACS Sustainable Chem. Eng.* 8 (2020) 15243.
- [65] P. Milbeo, F. Quintin, L. Moulat, C. Didierjean, J. Martinez, X. Bantreil, M. Calmès, F. Lamaty, *Tetrahedron Lett.* 63 (2021) 152706.